Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis

DOI record: { "DOI": "10.1007/s11096-024-01852-5", "ISSN": [ "2210-7703", "2210-7711" ], "URL": "http://dx.doi.org/10.1007/s11096-024-01852-5", "alternative-id": [ "1852" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "25 August 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "2 December 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "21 December 2024" }, { "group": { "label": "Conflicts of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors have no conflicts of interest to declare." } ], "author": [ { "affiliation": [], "family": "Stoiber", "given": "Alina", "sequence": "first" }, { "affiliation": [], "family": "Gray", "given": "Gwen", "sequence": "additional" }, { "affiliation": [], "family": "Sailer", "given": "Gudrun", "sequence": "additional" }, { "affiliation": [], "family": "Huf", "given": "Wolfgang", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-2659-6901", "affiliation": [], "authenticated-orcid": false, "family": "Tonna", "given": "Antonella", "sequence": "additional" } ], "container-title": "International Journal of Clinical Pharmacy", "container-title-short": "Int J Clin Pharm", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2024, 12, 21 ] ], "date-time": "2024-12-21T08:14:26Z", "timestamp": 1734768866000 }, "deposited": { "date-parts": [ [ 2024, 12, 21 ] ], "date-time": "2024-12-21T09:06:55Z", "timestamp": 1734772015000 }, "indexed": { "date-parts": [ [ 2024, 12, 22 ] ], "date-time": "2024-12-22T05:06:19Z", "timestamp": 1734843979398, "version": "3.32.0" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 12, 21 ] ] }, "language": "en", "license": [ { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 12, 21 ] ], "date-time": "2024-12-21T00:00:00Z", "timestamp": 1734739200000 } }, { "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 12, 21 ] ], "date-time": "2024-12-21T00:00:00Z", "timestamp": 1734739200000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s11096-024-01852-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s11096-024-01852-5/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s11096-024-01852-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1007", "published": { "date-parts": [ [ 2024, 12, 21 ] ] }, "published-online": { "date-parts": [ [ 2024, 12, 21 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "1852_CR1", "unstructured": "Center for Disease Control and Prevention (CDC). People with certain medical conditions and Covid-19 risk factors. CDC. 2024. http://www.cdc.gov/covid/risk-factors/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Accessed 23 Nov 2024." }, { "key": "1852_CR2", "unstructured": "Center for Disease Control and Prevention (CDC). Types of Covid-19 treatment. CDC. 2024. http://www.cdc.gov/covid/treatment/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html Accessed 23 Nov 2024." }, { "DOI": "10.1056/NEJMcp2009575", "author": "DA Berlin", "doi-asserted-by": "publisher", "first-page": "2451", "journal-title": "N Engl J Med", "key": "1852_CR3", "unstructured": "Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383:2451–60. https://doi.org/10.1056/NEJMcp2009575.", "volume": "383", "year": "2020" }, { "author": "Y Chao", "first-page": "572", "journal-title": "Hum Biol", "key": "1852_CR4", "unstructured": "Chao Y, Haiqiang L, Daoquan W, et al. A realworld Pharmacovigilance study of FDA adverse event reporting system (FAERS) events for paxlovid and molnupiravir. Hum Biol. 2024;94:572–80.", "volume": "94", "year": "2024" }, { "key": "1852_CR5", "unstructured": "Electronic Medicines Compendium (EMC). Paxlovid 150 mg/100 mg film-coated tablets—summary of product characteristics (SmPC)-(emc). EMC. 2024. https://www.medicines.org.uk/emc/product/13145/smpc. Accessed 23 Nov 2024." }, { "key": "1852_CR6", "unstructured": "Liverpool Interaction Group. Evaluating the drug-drug interaction risk of COVID-19 therapies (licensed or under clinical investigation). University of Liverpool. 2022. http://www.covid19-druginteractions.org/prescribing_resources/methods-metabolism. Accessed 23 Nov 2024." }, { "DOI": "10.3109/07853890.2011.572905", "author": "MW Hull", "doi-asserted-by": "publisher", "first-page": "375", "journal-title": "Ann Med", "key": "1852_CR7", "unstructured": "Hull MW, Montaner JSG. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 2011;43:375–88. https://doi.org/10.3109/07853890.2011.572905.", "volume": "43", "year": "2011" }, { "key": "1852_CR8", "unstructured": "World Health Organization (WHO). WHO model list of essential medicines—22nd list, 2021. WHO. 2021. https://www.who.int/publications-detail-redirect/WHO-MHP-HPS-EML-2021.02. Accessed 23 Nov 2024." }, { "key": "1852_CR9", "unstructured": "National Health Service (NHS). Chronic kidney disease—Diagnosis—NHS. NHS. 2019. https://www.nhs.uk/conditions/kidney-disease/diagnosis/. Accessed 14 March 2023." }, { "DOI": "10.1136/bmj.q59", "author": "E Mahase", "doi-asserted-by": "publisher", "first-page": "59", "journal-title": "Br Med J", "key": "1852_CR10", "unstructured": "Mahase E. Covid-19: NICE plans to expand Paxlovid eligibility to 1 million more people. Br Med J. 2024;384:59. https://doi.org/10.1136/bmj.q59.", "volume": "384", "year": "2024" }, { "DOI": "10.1136/bmj.o1695", "author": "JH Tanne", "doi-asserted-by": "publisher", "first-page": "1659", "journal-title": "Br Med J", "key": "1852_CR11", "unstructured": "Tanne JH. Covid-19: FDA authorises pharmacists to prescribe Paxlovid. Br Med J. 2022;378:1659. https://doi.org/10.1136/bmj.o1695.", "volume": "378", "year": "2022" }, { "DOI": "10.1093/ajhp/zxac163", "author": "K Traynor", "doi-asserted-by": "publisher", "first-page": "1126", "journal-title": "Am J Health Syst Pharm", "key": "1852_CR12", "unstructured": "Traynor K. Québec authorizes pharmacists to prescribe Paxlovid. Am J Health Syst Pharm. 2022;79:1126–7. https://doi.org/10.1093/ajhp/zxac163.", "volume": "79", "year": "2022" }, { "key": "1852_CR13", "unstructured": "Bundesministerium für Finanzen. RIS [Rechtsinformationssystem des Bundes]—Rezeptpflichtgesetz—Bundesrecht konsolidiert, Fassung vom 22.03.2023. Bundesministerium für Finanzen. 2023. [Federal Ministry of Finance. RIS (Federal Information System for Laws)—Compulsory Prescription Act—Federal law consolidated, version dated March 22, 2023. Federal Ministry of Finance. 2023.] https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10010351. Accessed 22 Mar 2023." }, { "DOI": "10.11613/BM.2012.031", "author": "M McHugh", "doi-asserted-by": "publisher", "first-page": "276", "issue": "3", "journal-title": "Biochem Med (Zagreb)", "key": "1852_CR14", "unstructured": "McHugh M. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–82.", "volume": "22", "year": "2012" }, { "key": "1852_CR15", "unstructured": "The University of Liverpool. Liverpool COVID-19 drug interactions. The University of Liverpool. 2023. https://www.covid19-druginteractions.org/checker#. Accessed 23 Nov 2024." }, { "key": "1852_CR16", "unstructured": "Liverpool Interaction Group. Interactions with outpatient medicines & Nirmatrelvir/ritonavir (NMV/r). University of Liverpool. 2023. www.covid19-druginteractions.org/prescribing_resources/paxlovid-outpatient-medicines. Accessed 23 Nov 2024." }, { "DOI": "10.18553/jmcp.2023.22366", "author": "E Igho-Osagie", "doi-asserted-by": "publisher", "first-page": "509", "journal-title": "J Manag Care Spec Pharm", "key": "1852_CR17", "unstructured": "Igho-Osagie E, Puenpatom A, Williams MG, et al. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy. J Manag Care Spec Pharm. 2023;29:509–28. https://doi.org/10.18553/jmcp.2023.22366.", "volume": "29", "year": "2023" }, { "DOI": "10.1073/pnas.2221857120", "author": "Y Kim", "doi-asserted-by": "publisher", "first-page": "e2221857120", "journal-title": "Proc Natl Acad Sci", "key": "1852_CR18", "unstructured": "Kim Y, Ryu JY, Kim HU, et al. Computational prediction of interactions between Paxlovid and prescription drugs. Proc Natl Acad Sci. 2023;120:e2221857120. https://doi.org/10.1073/pnas.2221857120.", "volume": "120", "year": "2023" }, { "DOI": "10.1002/cpt.2646", "author": "C Marzolini", "doi-asserted-by": "publisher", "first-page": "1191", "journal-title": "Clin Pharmacol Ther", "key": "1852_CR19", "unstructured": "Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral Nirmatrelvir/ritonavir (Paxlovid) and comedications. Clin Pharmacol Ther. 2022;112:1191–200. https://doi.org/10.1002/cpt.2646.", "volume": "112", "year": "2022" }, { "DOI": "10.1002/phar.2860", "author": "X Xiao", "doi-asserted-by": "publisher", "first-page": "1251", "journal-title": "Pharmacotherapy", "key": "1852_CR20", "unstructured": "Xiao X, Mehta HB, Curran J, et al. Potential drug-drug interactions among US adults treated with nirmatrelvir/ritonavir: a cross-sectional study of the National Covid Cohort Collaborative (N3C). Pharmacotherapy. 2023;43:1251–61. https://doi.org/10.1002/phar.2860.", "volume": "43", "year": "2023" }, { "DOI": "10.3390/pharmacy11030087", "author": "D Kieck", "doi-asserted-by": "publisher", "first-page": "87", "journal-title": "Pharmacy (Basel)", "key": "1852_CR21", "unstructured": "Kieck D, Mahalick L, Vo TT. Medication-related problems identified and addressed by pharmacists dispensing COVID-19 antivirals at a community pharmacy. Pharmacy (Basel). 2023;11:87. https://doi.org/10.3390/pharmacy11030087.", "volume": "11", "year": "2023" }, { "DOI": "10.1016/j.japh.2023.04.010", "author": "DB Portman", "doi-asserted-by": "publisher", "first-page": "1237", "journal-title": "J Am Pharm Assoc", "key": "1852_CR22", "unstructured": "Portman DB, Scolese CJ. Facilitating oral COVID-19 therapy utilization through a pharmacy consult service. J Am Pharm Assoc. 2023;63:1237–41. https://doi.org/10.1016/j.japh.2023.04.010.", "volume": "63", "year": "2023" }, { "DOI": "10.1345/aph.1M187", "author": "Y Hassan", "doi-asserted-by": "publisher", "first-page": "1598", "journal-title": "Ann Pharmacother", "key": "1852_CR23", "unstructured": "Hassan Y, Al-Ramahi RJ, Aziz NA, et al. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease. Ann Pharmacother. 2009;43:1598–605. https://doi.org/10.1345/aph.1M187.", "volume": "43", "year": "2009" }, { "author": "MP Doogue", "first-page": "69", "issue": "2", "journal-title": "Clin Biochem Rev", "key": "1852_CR24", "unstructured": "Doogue MP, Polasek TM. Drug dosing in renal disease. Clin Biochem Rev. 2011;32(2):69–73.", "volume": "32", "year": "2011" }, { "DOI": "10.1016/j.ijcard.2015.10.206", "author": "T Roblek", "doi-asserted-by": "publisher", "first-page": "647", "journal-title": "Int J Cardiol", "key": "1852_CR25", "unstructured": "Roblek T, Deticek A, Leskovar B, et al. Clinical-pharmacist intervention reduces clinically relevant drug–drug interactions in patients with heart failure: a randomized, double-blind, controlled trial. Int J Cardiol. 2016;203:647–52. https://doi.org/10.1016/j.ijcard.2015.10.206.", "volume": "203", "year": "2016" }, { "DOI": "10.1186/s40780-018-0125-z", "author": "Y Tasaka", "doi-asserted-by": "publisher", "first-page": "33", "journal-title": "J Pharm Health Care Sci", "key": "1852_CR26", "unstructured": "Tasaka Y, Tanaka A, Yasunaga A, et al. Potential drug-related problems detected by routine pharmaceutical interventions: safety and economic contributions made by hospital pharmacists in Japan. J Pharm Health Care Sci. 2018;4:33. https://doi.org/10.1186/s40780-018-0125-z.", "volume": "4", "year": "2018" }, { "DOI": "10.4103/jrpp.JRPP_18_88", "author": "M Shafiekhani", "doi-asserted-by": "publisher", "first-page": "143", "journal-title": "J Res Pharm Pract", "key": "1852_CR27", "unstructured": "Shafiekhani M, Moosavi N, Firouzabadi D, et al. Impact of clinical pharmacist’s interventions on potential drug-drug interactions in the cardiac care units of two university hospitals in Shiraz, South of Iran. J Res Pharm Pract. 2019;8:143–8. https://doi.org/10.4103/jrpp.JRPP_18_88.", "volume": "8", "year": "2019" }, { "DOI": "10.5005/jp-journals-10071-23919", "author": "M Aghili", "doi-asserted-by": "publisher", "first-page": "1226", "journal-title": "Indian J Crit Care Med", "key": "1852_CR28", "unstructured": "Aghili M, Kasturirangan MN. Management of drug-drug interactions among critically ill patients with chronic kidney disease: impact of clinical pharmacist’s interventions. Indian J Crit Care Med. 2021;25:1226–31. https://doi.org/10.5005/jp-journals-10071-23919.", "volume": "25", "year": "2021" }, { "DOI": "10.1007/s11096-015-0199-8", "author": "SH Chau", "doi-asserted-by": "publisher", "first-page": "46", "journal-title": "Int J Clin Pharm", "key": "1852_CR29", "unstructured": "Chau SH, Jansen AP, van de Ven PM, et al. Clinical medication reviews in elderly patients with polypharmacy: a cross-sectional study on drug-related problems in the Netherlands. Int J Clin Pharm. 2016;38:46–53. https://doi.org/10.1007/s11096-015-0199-8.", "volume": "38", "year": "2016" }, { "DOI": "10.1002/hsr2.1971", "author": "JC Kanninen", "doi-asserted-by": "publisher", "first-page": "e1971", "journal-title": "Health Sci Rep", "key": "1852_CR30", "unstructured": "Kanninen JC, Toivo T, Airaksinen M, et al. Collaborative medication reviews in community pharmacies-drug-related problems and the process of communicating them with physicians: a retrospective validation study. Health Sci Rep. 2024;7:e1971. https://doi.org/10.1002/hsr2.1971.", "volume": "7", "year": "2024" }, { "DOI": "10.1016/j.sapharm.2016.10.016", "author": "HM Seidling", "doi-asserted-by": "publisher", "first-page": "1127", "journal-title": "Res Soc Adm Pharm", "key": "1852_CR31", "unstructured": "Seidling HM, Send AFJ, Bittmann J, et al. Medication review in German community pharmacies—Post-hoc analysis of documented drug-related problems and subsequent interventions in the ATHINA-project. Res Soc Adm Pharm. 2017;13:1127–34. https://doi.org/10.1016/j.sapharm.2016.10.016.", "volume": "13", "year": "2017" }, { "DOI": "10.3389/fphar.2020.01176", "author": "E Schindler", "doi-asserted-by": "publisher", "first-page": "1176", "journal-title": "Front Pharmacol", "key": "1852_CR32", "unstructured": "Schindler E, Hohmann C, Culmsee C. Medication review by community pharmacists for type 2 diabetes patients in routine care: results of the DIATHEM-study. Front Pharmacol. 2020;11:1176. https://doi.org/10.3389/fphar.2020.01176.", "volume": "11", "year": "2020" }, { "DOI": "10.1016/j.sapharm.2021.07.017", "author": "DE Michel", "doi-asserted-by": "publisher", "first-page": "2944", "journal-title": "Res Social Adm Pharm", "key": "1852_CR33", "unstructured": "Michel DE, Tonna AP, Dartsh DC, Weidmann AE. Experiences of key stakeholders with the implementation of medication reviews in community pharmacies: a systematic review using the consolidated framework for implementation research (CFIR). Res Social Adm Pharm. 2022;18:2944–61. https://doi.org/10.1016/j.sapharm.2021.07.017.", "volume": "18", "year": "2022" } ], "reference-count": 33, "references-count": 33, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s11096-024-01852-5" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid® prescribing: a descriptive analysis", "type": "journal-article", "update-policy": "https://doi.org/10.1007/springer_crossmark_policy" }